Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseasesFelzartamab is an investigational...

Related Keywords

Taiwan ,Hong Kong ,Minnesota ,United States ,Macau ,China ,Stockholm ,Sweden ,Olmsted County ,Japan ,Cambridge ,Cambridgeshire ,United Kingdom ,Chuck Triano ,Jack Cox ,Travis Murdoch ,Priya Singhal ,Morgan Warners ,Facebook ,Exchange Commission ,Head Of Development At Biogen ,Goodwin Procter ,Youtube ,Linkedin ,Bofa Securities Inc ,Drug Administration ,Covington Burling ,Human Immunology Biosciences Inc ,Biogen Inc ,Nasdaq ,European Renal Association ,Goldman Sachs Co ,A Single Center ,Clinical Research ,Human Immunology Biosciences ,Breakthrough Therapy Designation ,Orphan Drug Designation ,Chief Executive Officer ,San Francisco Bay Area ,Goldman Sachs ,Bofa Securities ,Antibody Mediated Rejection ,Kidney Transplant ,Primary Membranous Nephropathy ,Immunology Biosciences ,Monograph Capital ,Alpha Wave Global ,Arkin Bio Capital ,Jeito Capital ,Viking Global ,Safe Harbor ,Low Levels ,Low Positiveb Flow Crossmatch ,Highly Sensitized Transplant Candidates ,Mediated Rejection Implies ,Poor Prognosis ,Kidney Transplantation ,Results From ,Severe Membranous Nephropathy ,Month Trial ,Life Expectancy ,Patients From ,Southeastern United States With Iga ,